---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005536"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:39:01.972318+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Imunon appoints Dr. Douglas Faller as CMO; Phase 3 trial on track for Q1 2025

## Summary
- Dr. Douglas Faller appointed Chief Medical Officer effective Feb 18, 2025, to lead clinical strategy.
- Lead program IMNN-001 for advanced ovarian cancer on track to enter Phase 3 pivotal trial in Q1 2025.
- Compensation: $480k salary, 40% bonus target, inducement options for 100,000 shares with 4-year vesting.
- Dr. Faller brings 30+ years of oncology/immunology experience from Takeda, Skyhawk, and academic roles.

## SEC filing metadata
- accession: 0001493152-25-005536
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/0001493152-25-005536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005536
- JSON: https://secwatch.observer/filing/0001493152-25-005536.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005536.txt

## Key facts
- Executive change
  Douglas Faller was appointed as Chief Medical Officer at Imunon, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On February 9, 2025, the Board of Directors of Imunon, Inc. (the “Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/0001493152-25-005536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.